OncLive.com· @OncLive · X·· 2 天前评分70
正文 · 原文
🎯 62% confirmed ORR, 12.2-month median DOR, and 11.1-month median PFS with mocertatug rezetecan at the phase 3 dose in platinum-resistant ovarian cancer. Dana M. Chase, MD, of @UCLAHealthJCCC, on where B7-H4–targeted ADCs may fit 👇 #ESMO26 #gyncsm #ovca @myESMO https://hubs.li/Q04CjPYn0
81 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源：OncLive.com · x.com